Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 04 04:00PM ET
15.71
Dollar change
+0.83
Percentage change
5.58
%
Index- P/E- EPS (ttm)- Insider Own25.25% Shs Outstand25.57M Perf Week2.61%
Market Cap380.65M Forward P/E- EPS next Y-2.58 Insider Trans11.31% Shs Float18.11M Perf Month-
Income- PEG- EPS next Q-0.51 Inst Own24.26% Short Float4.27% Perf Quarter-
Sales- P/S- EPS this Y20.60% Inst Trans- Short Ratio1.91 Perf Half Y-
Book/sh-1.50 P/B- EPS next Y-19.73% ROA- Short Interest0.77M Perf Year-
Cash/sh2.00 P/C7.87 EPS next 5Y- ROE- 52W Range12.83 - 24.00 Perf YTD-24.11%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-34.54% Beta-
Dividend TTM- Quick Ratio8.85 Sales past 5Y-100.00% Gross Margin- 52W Low22.45% ATR (14)2.09
Dividend Ex-Date- Current Ratio8.85 EPS Y/Y TTM- Oper. Margin- RSI (14)- Volatility12.79% -
Employees- Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.20 Target Price32.33
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q- Payout- Rel Volume0.48 Prev Close14.88
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume405.46K Price15.71
SMA20-1.92% SMA50-1.92% SMA200-1.92% Trades Volume194,448 Change5.58%
Date Action Analyst Rating Change Price Target Change
Feb-27-24Initiated William Blair Outperform
Feb-27-24Initiated TD Cowen Outperform
Feb-27-24Initiated Stifel Buy $32
Feb-27-24Initiated Robert W. Baird Outperform $32
Feb-27-24Initiated Jefferies Buy $33
Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients' brain activity and behavior to rapidly develop highly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Alpha Wave Global, LP10% OwnerFeb 06Buy16.00600,0009,600,0003,707,757Feb 08 04:32 PM
Savitz AdamCHIEF MEDICAL OFFICERFeb 06Buy16.0017,000272,00024,851Feb 07 04:38 PM
Etkin AmitPRESIDENT AND CEOFeb 06Buy16.003,12550,0001,205,465Feb 07 04:36 PM
Smith Nicholas ConradCHIEF FINANCIAL OFFICERFeb 06Buy16.001,56325,0081,563Feb 07 04:40 PM